Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Success in CTOs caused by restenosis lowers cardiac mortality

Courtesy of Dr. Carlos Fava.

Success in CTOs Caused by Restenosis Lowers Cardiac MortalityNowadays, chronic total occlusions (CTO) due to in-stent restenosis (ISR) represent 5%-25% of all coronary angioplasties. These lesions pose a new and true challenge, since CTOs are often associated with stent-related problems (fractures, lack of expansion, overlapping, deformation), extreme tortuosity, severe calcification, tandem lesions after CTO, and aorto-ostial lesions, with little evidence on outcomes and evolution.

 

This study included 233 patients with CTO due to ISR. There was procedural success in 192 cases (82.4%).

 

Populations were similar: the mean age was 62 years old (most patients were male), 40% of all patients had diabetes, 6% had undergone previous myocardial revascularization surgery (MRS), 10% presented peripheral vascular disease, and 5% had previously experienced a stroke. As regards CTO, 34% of patients experienced it in the left anterior descending artery, 47% in the right coronary artery, and 18% in the left circumflex artery. Lesion length was 28 mm; 16% of patients presented severe calcification, 22% presented moderate-severe tortuosity, 37% experienced bridging collaterals, 44% had a J-CTO score >3, and in 13% of cases CTO had ostial location.

 

The rechanneling failure rate was higher for CTOs with a J-CTO score >3, those in the left circumflex artery, and in ostial lesions.

 

Transfemoral access was more frequent in the successful group (92% vs. 80%; p = 00.03), with a trend for higher usage of 8-Fr catheters. The antegrade approach was the one most used (94%). Complications during the procedure occurred in 9.7% of all cases (coronary dissection in 5.2% of all patients and coronary perforation without tamponade in 4.5% of them).

 

The length of follow-up was 20 months. There was no difference regarding major adverse cardiac events (MACE) (19%), but the group of patients with failed procedures presented higher rates of cardiac death (8.3% vs. 3%), all-cause death (11.4% vs. 4.7%; p = 0.09), and the need for MRS (13.7% vs. 1.7%). In the successful rechanneling group, the rate of target-lesion revascularization was 15%, the rate of reocclusion was 6%, and the rate of definite/probable thrombosis was 1.8%.

 

Conclusion

Percutaneous treatment of CTO due to ISR in contemporary practice shows a high success rate with good long-term results. Identified angiographic and procedural predictors may contribute to improve procedural outcomes through better patient selection.

 

Editorial Comment

This is one of the few studies analyzing only CTOs due to ISR. In the future, the number of these cases will surely increase till they constitute a subgroup requiring a management strategy different from that for traditional CTOs.

 

The most important aspect of this analysis is that successful angioplasty for a CTO due to ISR showed significant improvement of the cardiac death rate. This may possibly be due to the fact that the study treated patients with prior interventions, as opposed to what happens with pure CTOs.

 

Furthermore, the success rate increased over time (surely due to the learning curve), without using drug-eluting stents in all patients. In any case, outcomes during follow-up were still good.

 

One of the present limitations is that transfemoral access is still used along with a high rate of use of 8-Fr catheters. In the future, this procedure may possibly be carried out through a transradial access with dedicated radial introducers (Glidesheath Slender or similar) and lower-gauge diameter.

 

Courtesy of Dr. Carlos Fava.

 

Original title: Percutaneous Intervention in Chronic Total Coronary Occlusions Caused by In-Stent Restenosis: Procedural Results and Long-Term Clinical Outcomes in the TORO (Spanish registry of chronic Total occlusion secondary to an occlusive in-stent RestenOsis) Multicentre Registry.

Reference: Jose M. de la Torre Hernandez, et al. EuroIntervention 2017;13:e219-226


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...